Repligen Corporation is a leading global provider of bioprocessing technologies and solutions that support the development and manufacture of biologic drugs. Specializing in high-value consumable prod... Repligen Corporation is a leading global provider of bioprocessing technologies and solutions that support the development and manufacture of biologic drugs. Specializing in high-value consumable products, Repligen plays a pivotal role in the biotechnology and pharmaceutical sectors by supplying sophisticated products such as Protein A affinity ligands, advanced filtration systems, and ready-to-use chromatography columns—essential tools for the purification and production of complex biologics, including monoclonal antibodies. The company’s innovative portfolio serves major life sciences firms and contract manufacturing organizations worldwide, helping to increase efficiency, reliability, and yield in drug production processes. Headquartered in Waltham, Massachusetts, Repligen Corporation maintains a strong manufacturing footprint in Europe, underscoring its global reach and commitment to supporting the rapidly expanding biopharmaceutical market. With over 1,700 employees and continuous investment in research and development, Repligen is recognized for driving advancements in bioprocessing that are critical to meeting the growing demand for biologic therapies. Its contributions are integral to the lifecycle of next-generation medicines, making it a key enabler for both established and emerging biopharma companies.